Abstract: Techniques of self-checkout alerts based on packaging detection. A given bag type of a bag selected at a self-checkout kiosk is identified out of a bag types available from a bag dispenser associated with the self-checkout kiosk, the bag being an empty bag. A weight range of the empty bag is identified based on the given bag type. An allowed weight range of a combination of the empty bag and a desired item is determined based on the weight range of the empty bag, a weight of the desired item as measured by a terminal scale, and at least one of a measurement tolerance of the terminal scale and a measurement tolerance of a platform scale. A loss prevention alert is generated, and a transaction at the self-checkout kiosk is paused, upon determining that the allowed weight range is exceeded.

Abstract: Techniques for self-checkout alert reduction based on packaging detection. A deflection in a first bag reservoir associated with a self-checkout kiosk is determined. The first bag reservoir is positioned adjacent to a packing area and includes a first type of bags. The self-checkout kiosk includes a terminal scale and further includes a platform scale in the packing area. That an empty bag is retrieved from the first bag reservoir is determined based on the deflection in the first bag reservoir. A bag type and a weight range are identified for the empty bag. An allowed weight range of a combination of the empty bag and a desired item is then determined. Presence of the empty bag on the platform scale is prevented from causing a loss prevention alert to be generated when the desired item has been placed in the empty bag on the platform scale.

Abstract: The present disclosure provides improved packaging detection at self-checkout kiosks by identifying a given bag type for a bag selected at a self-checkout kiosk out of a plurality of bag types available from a bag dispenser associated with the self-checkout kiosk; identifying a weight range for the given bag type; in response to determining that the bag has been moved to a packing area of the self-checkout kiosk, comparing a first weight in the packing area from before the bag was moved to the packing area with a second weight in the packing area that includes the bag; and in response to a difference between the first weight and the second weight falling outside of the weight range, generating a loss prevention alert and pausing a transaction at the self-checkout kiosk.

Abstract: Novel inhibitors of the bromodomain of Brahma-related gene 1 (BRG1) are described. Also described are methods of treating glioblastoma using inhibitors of the BRG1 bromodomain in combination with chemotherapeutics, such as DNA alkylating agents. As described herein, the inhibitors sensitize glioblastoma cells, including chemoresistant glioblastoma cells, to DNA alkylating agents, for example, temozolomide and carmustine.

Abstract: The present disclosure provides improved packaging detection at self-checkout kiosks by identifying a given bag type for a bag selected at a self-checkout kiosk out of a plurality of bag types available from a bag dispenser associated with the self-checkout kiosk; identifying a weight range for the given bag type; in response to determining that the bag has been moved to a packing area of the self-checkout kiosk, comparing a first weight in the packing area from before the bag was moved to the packing area with a second weight in the packing area that includes the bag; and in response to a difference between the first weight and the second weight falling outside of the weight range, generating a loss prevention alert and pausing a transaction at the self-checkout kiosk.

Abstract: A system for loading fry bulk materials into a tank trailer includes a blower assembly mounted on a tank truck that is in pneumatic communication with the interior of a tank of the tank trailer through at least one conduit. The blower assembly includes a blower and a blower filter in pneumatic communication with the blower through a suction line. The blower assembly further includes a vacuum gauge for monitoring the vacuum pressure of the airflow between the blower filter and the blower and an optional check valve for passing the airflow from the ambient atmosphere in the event that the vacuum pressure of the airflow exceeds a predetermined maximum vacuum pressure for safe operation of the blower. The predetermined maximum vacuum pressure may be no more than about five inches of mercury vacuum pressure (5 in-Hg; 2.46 psi). An operating vacuum pressure of the blower may be between about seventeen inches of mercury (17 in-Hg; 8.35 psi) and about five inches of mercury (5 in-Hg; 2.46 psi).

Abstract: Disclosed is a five-feature pharmacophore model of LPA2 receptor specific agonists. Compounds may be identified as agonists of the LPA2 receptor using the five-feature pharmacophore model.

Abstract: A hitch cover is shown and described. The hitch cover may include a base having first and second surfaces, the second surface having at least one engagement member attached thereto. The hitch cover may also include a mounting bracket selectively attached to the at least one engagement member of the base and extending from the second surface wherein the mounting bracket is configured to selectively engage a hitch receiver tube.

Abstract: A system for loading fry bulk materials into a tank trailer includes a blower assembly mounted on a tank truck that is in pneumatic communication with the interior of a tank of the tank trailer through at least one conduit. The blower assembly includes a blower and a blower filter in pneumatic communication with the blower through a suction line. The blower assembly further includes a vacuum gauge for monitoring the vacuum pressure of the airflow between the blower filter and the blower and an optional check valve for passing the airflow from the ambient atmosphere in the event that the vacuum pressure of the airflow exceeds a predetermined maximum vacuum pressure for safe operation of the blower. The predetermined maximum vacuum pressure may be no more than about five inches of mercury vacuum pressure (5 in-Hg; 2.46 psi). An operating vacuum pressure of the blower may be between about seventeen inches of mercury (17 in-Hg; 8.35 psi) and about five inches of mercury (5 in-Hg; 2.46 psi).

Abstract: A hitch cover is shown and described. The hitch cover may include a base having first and second surfaces, the second surface having at least one engagement member attached thereto. The hitch cover may also include a mounting bracket selectively attached to the at least one engagement member of the base and extending from the second surface wherein the mounting bracket is configured to selectively engage a hitch receiver tube.

Abstract: The disclosed apparatus, systems and methods relate to a hand disguise for hunters. The hand disguise has a glove and a sleeve which is adapted to fit one or more fingers. The sleeve is also connected to a tail region, which is adapted to resemble the tail of a small animal. In certain applications, the disguise can be used by a hunter as a means of mimicking the behavior of a small animal. Various disguises include real or artificial fur or feathers.

Abstract: Disclosed are compounds effective for inhibiting cellular apoptosis and for protecting cells and tissues from the apoptotic effects of chemotherapeutic agents and/or ionizing radiation. Compounds of the invention act as agonists of the LPA2 receptor. Compounds of the invention comprise non-lipid benzoic acid derivatives. Further disclosed is a pharmacophore of LPA2 receptor.

Abstract: A hitch cover is shown and described. The hitch cover may include a base having first and second surfaces, the second surface having at least one engagement member attached thereto. The hitch cover may also include a mounting bracket selectively attached to the at least one engagement member of the base and extending from the second surface wherein the mounting bracket is configured to selectively engage a hitch receiver tube.

Abstract: Indole derivatives and analog compounds and pharmaceutical compositions comprising the same are provided. Also provided are methods of using these compounds to inhibit tubulin polymerization in a cell associated with a proliferative disease or to treat a cancer.

Abstract: Disclosed are compounds according to formula (I) as well as pharmaceutical compositions which include those compounds. Also disclosed are methods of using such compounds, which have activity as agonists or as antagonists of LPA receptors; such methods including inhibiting LPA activity on an LPA receptor, modulating LPA receptor activity, treating cancer, enhancing cell proliferation, treating a wound, treating apoptosis or preserving or restoring function in a cell, tissue, or organ, culturing cells, preserving organ or tissue function, and treating a dermatological condition.

Abstract: This invention provides substituted acylanilide compounds and uses thereof in treating a variety of diseases or conditions in a subject, including, inter alia, a muscle wasting disease and/or disorder or a bone-related disease and/or disorder.

Abstract: This invention provides SARM compounds and uses thereof in treating a variety of diseases or conditions in a subject, including, inter alia, a muscle wasting disease and/or disorder or a bone-related disease and/or disorder.

Abstract: This invention provides SARM compounds and uses thereof in treating a variety of diseases or conditions in a subject, including, inter-alia, muscle wasting diseases and/or disorders, bone-related diseases and/or disorders, diabetes, cardiovascular disease, renal disease and others.

Abstract: Disclosed are compounds that are effective for selectively killing cancer cells. Compounds have been demonstrated to be especially effective for killing glioma cells, while exhibiting low toxicity to normal cells.

Abstract: This invention provides use of a SARM compound or a composition comprising the same in treating a variety of diseases or conditions in a subject, including, inter-alia, a diabetes disease, and/or disorder such as cardiovascular disease, atherosclerosis, cerebrovascular conditions, diabetic nephropathy, diabetic neuropathy and diabetic retinopathy.